文献速递骨软组织肉瘤与黑色素瘤

新辅助免疫治疗时代黑色素瘤前哨淋巴结活检是否冗余

Sentinel lymph node biopsy in melanoma: Redundant in the neoadjuvant era.
PubMed 文献 · Eur J Cancer · 2026-09-10

该文基于关键黑色素瘤免疫治疗试验与MSLT-1试验数据,用马尔可夫模型模拟两种策略:前哨淋巴结活检阳性后辅助免疫治疗,对比省略前哨淋巴结活检、淋巴结复发后行新辅助抗PD-1联合抗CTLA-4治疗。结果显示省略活检策略使无远处转移生存提高8-19个百分点,获益幅度随Breslow厚度变化,提示需随机对照试验重新评估前哨淋巴结活检地位。

要点

  • 省略前哨淋巴结活检后以新辅助联合免疫治疗处理淋巴结复发,模型显示无远处转移生存提高8-19个百分点。
  • 获益幅度随Breslow厚度不同而变化,提示需按厚度分层评估策略。
  • 该模型结果支持开展国际随机对照试验重新评估前哨淋巴结活检在当代治疗中的角色。

核心结论

  • 在新辅助免疫治疗时代,省略前哨淋巴结活检可能改善黑色素瘤患者的肿瘤学结局。

研究设计与样本

  • 研究利用关键黑色素瘤免疫治疗试验和MSLT-1试验数据,构建马尔可夫模型模拟两种临床场景。
  • 场景一为前哨淋巴结活检阳性后行辅助免疫治疗,场景二为省略前哨淋巴结活检并临床观察、淋巴结复发后行新辅助抗PD-1联合抗CTLA-4治疗。
  • 主要模拟终点为无远处转移生存。

主要发现

  • 与活检阳性后辅助免疫治疗相比,省略前哨淋巴结活检并以新辅助联合免疫治疗处理淋巴结复发,使无远处转移生存提高8-19个百分点。
  • 获益幅度根据Breslow厚度不同而变化。

临床怎么用

  • 对可切除、临床可检测的III期黑色素瘤,新辅助免疫治疗已被视为优于辅助免疫治疗的策略。
  • 对微观III期病变,辅助免疫治疗通常为标准治疗,但缺乏生存获益提示需重新评估前哨淋巴结活检加辅助治疗的路径。
  • 省略前哨淋巴结活检可能避免手术、促进更有效的全身治疗、减少所需免疫治疗剂量并可能改善长期肿瘤学结局。

局限性

  • 研究基于模型模拟而非前瞻性随机对照试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant immunotherapy has emerged as a superior strategy to adjuvant immunotherapy for patients with resectable, clinically detectable stage III melanoma, significantly improving event-free survival. In microscopic stage III disease, adjuvant immunotherapy is generally considered standard of care, although lack of survival benefit prompts re-evaluation of this sentinel lymph node biopsy (SLND) plus adjuvant therapy approach. Specifically, omission of SLNB may not only spare patients from surgery but also facilitate more effective systemic therapy, reduce the required number of immunotherapy doses, and potentially improve long-term oncological outcomes. METHODS: Data from pivotal melanoma immunotherapy trials and MSLT-1 trail were used to model two clinical scenarios: (1) SLNB followed by adjuvant immunotherapy in patients with a positive sentinel lymph node, and (2) omission of SLNB and clinical observation. A subsequent nodal recurrence then treated using neoadjuvant anti-PD-1 plus anti-CTLA-4 immunotherapy. Distant metastasis-free survival (DMFS) was simulated using a Markov model. FINDINGS: Omission of SLNB with treatment of nodal recurrence using neoadjuvant combination immunotherapy resulted in a 8-19 percentage point improvement in DMFS compared with the SLNB strategy followed by adjuvant immunotherapy in patients with a positive sentinel lymph node. The magnitude of benefit varied according to Breslow thickness. INTERPRETATION: Omitting SLNB may improve oncological outcomes in patients with melanoma in the era of neoadjuvant immunotherapy. These findings provide a compelling rationale for an international randomized controlled trial to re-evaluate the role of SLNB within contemporary melanoma treatments.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schurink AW, Janssen JC, van Hulst PL, et al. Sentinel lymph node biopsy in melanoma: Redundant in the neoadjuvant era. Eur J Cancer. 2026. PMID: 42748588. doi:10.1016/j.ejca.2026.117038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。